Stockscreener 앱 받기
121.48
3.20%
-4.02
시간 외 거래:
121.48
전일 마감가:
$125.50
열려 있는:
$125.635
하루 거래량:
10.14M
Relative Volume:
1.59
시가총액:
$150.83B
수익:
$29.79B
순이익/손실:
$9.22B
주가수익비율:
16.53
EPS:
7.3494
순현금흐름:
$10.23B
1주 성능:
-5.82%
1개월 성능:
-7.50%
6개월 성능:
+0.12%
1년 성능:
+10.35%
1일 변동 폭
$121.39
$125.64
1주일 범위
$121.39
$131.66
52주 변동 폭
$104.46
$157.29
길리어드 사이언스 Stock (GILD) Company Profile
명칭
Gilead Sciences Inc
전화
(650) 574-3000
주소
333 LAKESIDE DR, FOSTER CITY, CA
Compare GILD vs LLY, JNJ, ABBV, MRK, NVS
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
121.48 | 155.82B | 29.79B | 9.22B | 10.23B | 7.3494 |
LLY
Lilly Eli Co
|
1,136.37 | 1.02T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
238.49 | 570.51B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
224.95 | 398.27B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
119.09 | 295.39B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
148.12 | 284.53B | 54.66B | 13.58B | 16.05B | 7.0171 |
길리어드 사이언스 Stock (GILD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-10 | 개시 | Jefferies | Buy |
| 2026-02-20 | 개시 | Barclays | Equal Weight |
| 2026-02-11 | 재확인 | Needham | Buy |
| 2026-01-07 | 재개 | UBS | Buy |
| 2025-11-24 | 재개 | Truist | Buy |
| 2025-11-13 | 개시 | Scotiabank | Sector Outperform |
| 2025-08-19 | 업그레이드 | Daiwa Securities | Neutral → Outperform |
| 2025-08-08 | 업그레이드 | Truist | Hold → Buy |
| 2025-07-25 | 업그레이드 | Needham | Hold → Buy |
| 2025-04-22 | 재개 | Cantor Fitzgerald | Overweight |
| 2025-03-04 | 재확인 | Oppenheimer | Outperform |
| 2025-02-18 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2025-02-13 | 업그레이드 | DZ Bank | Hold → Buy |
| 2025-01-10 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | 재개 | BofA Securities | Buy |
| 2024-11-15 | 개시 | Wolfe Research | Outperform |
| 2024-11-14 | 개시 | Citigroup | Buy |
| 2024-11-08 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2024-10-21 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-10-17 | 개시 | Bernstein | Outperform |
| 2024-10-07 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2024-07-08 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2024-05-01 | 재확인 | Maxim Group | Buy |
| 2024-04-24 | 업그레이드 | HSBC Securities | Reduce → Hold |
| 2024-02-22 | 다운그레이드 | Truist | Buy → Hold |
| 2023-11-09 | 개시 | Deutsche Bank | Hold |
| 2023-09-08 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2023-09-06 | 개시 | HSBC Securities | Reduce |
| 2023-07-24 | 재확인 | Barclays | Equal Weight |
| 2023-05-16 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-28 | 재개 | Piper Sandler | Overweight |
| 2023-01-03 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-12-13 | 재개 | BofA Securities | Neutral |
| 2022-12-09 | 다운그레이드 | DZ Bank | Buy → Hold |
| 2022-10-31 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2022-10-28 | 재확인 | BMO Capital Markets | Market Perform |
| 2022-10-28 | 재확인 | Cowen | Outperform |
| 2022-10-28 | 재확인 | JP Morgan | Overweight |
| 2022-10-28 | 재확인 | Jefferies | Buy |
| 2022-10-28 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2022-10-28 | 재확인 | RBC Capital Mkts | Outperform |
| 2022-10-28 | 업그레이드 | Truist | Hold → Buy |
| 2022-10-28 | 재확인 | Wells Fargo | Equal Weight |
| 2022-10-04 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2022-07-13 | 개시 | Cantor Fitzgerald | Neutral |
| 2022-05-23 | 개시 | SVB Leerink | Mkt Perform |
| 2022-02-28 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-02 | 재확인 | BMO Capital Markets | Outperform |
| 2022-02-02 | 재확인 | BofA Securities | Neutral |
| 2022-02-02 | 재확인 | RBC Capital Mkts | Outperform |
| 2022-02-02 | 재확인 | Truist | Hold |
| 2022-02-02 | 재확인 | Wells Fargo | Equal Weight |
| 2022-01-28 | 업그레이드 | Argus | Hold → Buy |
| 2022-01-06 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-09 | 재개 | Wells Fargo | Equal Weight |
| 2021-12-06 | 개시 | Goldman | Neutral |
| 2021-11-19 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2021-11-19 | 재개 | Piper Sandler | Neutral |
| 2021-10-20 | 재개 | Cowen | Outperform |
| 2021-07-30 | 재확인 | BMO Capital Markets | Market Perform |
| 2021-07-30 | 재확인 | RBC Capital Mkts | Outperform |
| 2021-04-01 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2021-03-30 | 업그레이드 | Redburn | Neutral → Buy |
| 2021-01-19 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2021-01-04 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-11-03 | 재개 | Morgan Stanley | Equal-Weight |
| 2020-10-28 | 개시 | UBS | Neutral |
| 2020-09-30 | 재개 | Jefferies | Buy |
| 2020-09-15 | 업그레이드 | Maxim Group | Hold → Buy |
| 2020-07-31 | 재확인 | Credit Suisse | Neutral |
| 2020-07-31 | 재확인 | Morgan Stanley | Equal-Weight |
| 2020-07-31 | 재확인 | Piper Sandler | Overweight |
| 2020-07-31 | 재확인 | RBC Capital Mkts | Outperform |
| 2020-07-31 | 재확인 | SunTrust | Hold |
| 2020-07-31 | 재확인 | Wells Fargo | Equal Weight |
| 2020-07-20 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2020-06-03 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2020-05-26 | 업그레이드 | SunTrust | Sell → Hold |
| 2020-05-01 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-05-01 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2020-05-01 | 다운그레이드 | SunTrust | Hold → Sell |
| 2020-04-27 | 다운그레이드 | UBS | Buy → Neutral |
| 2020-04-20 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2020-04-20 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | 다운그레이드 | CFRA | Hold → Sell |
모두보기
길리어드 사이언스 주식(GILD)의 최신 뉴스
Can Gilead Sciences HIV Franchise Drive Long-Term Growth? - Zacks Investment Research
Deutsche Bank AG Decreases Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Shares Sold by BLI Banque de Luxembourg Investments - MarketBeat
4th Circ. Revives Ex-Gilead Worker's Defamation Suit - Law360
What I Wish I Knew About Hepatitis B: Personal Journeys Out of Asia - Gilead Sciences
Gilead, Merck Report Positive Phase III HIV Study Data, End NSCLC Study - Yahoo Finance
Gilead And Merck End Trodelvy-Keytruda Lung Cancer TrialGilead Sciences (NASDAQ:GILD), Merck & Co (NYS - Benzinga
Gilead Balances Trodelvy Setback With Once Weekly HIV Progress - simplywall.st
Gilead’s Mixed Trial News Puts HIV Progress And Oncology Risks In Focus - Yahoo Finance
Merck, Gilead report mixed outcomes in key lung cancer, HIV studies - BioPharma Dive
Ex-Gilead Worker Lands New Shot at Defamation Suit Over Firing - Bloomberg Law News
Merck, Gilead score in effort to develop the first weekly HIV pill - Fierce Pharma
As Gilead's Trodelvy stumbles in first-line lung cancer, all eyes turn to Merck, AZ and Daiichi rivals - Fierce Pharma
Gilead and MSD’s once-weekly HIV pill meets primary endpoints in Phase III trials - Clinical Trials Arena
Merck, Gilead serve ‘sweet and sour’ spread after HIV win, cancer stumble - BioSpace
A Quick Look at Today's Ratings for Gilead Sciences(GILD.US), With a Forecast Between $155 to $165 - Moomoo
Cantor Fitzgerald reiterates Gilead stock rating on HIV trial data By Investing.com - Investing.com South Africa
Merck and Gilead discontinue Phase III KEYNOTE-D46/EVOKE-03 study - The Pharma Letter
WINTON GROUP Ltd Sells 56,799 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Franklin Resources Inc. Sells 169,087 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead-MSD once-weekly oral HIV regimen meets Phase III endpoints - European Pharmaceutical Review
Gilead's lung cancer bid for Trodelvy hits wall, but HIV studies deliver better news - FirstWord Pharma
[Press release] Gilead and Merck announce positive topline results from two Phase 3 studies evaluating islatravir/lenacapavir, an oral once-weekly HIV treatment - European AIDS Treatment Group
Merck (MRK) and Gilead Sciences (GILD) Achieve Key Trial Milesto - GuruFocus
Merck, Gilead share positive phase 3 results from combination HIV pill - Seeking Alpha
Gilead and Merck’s Once-Weekly HIV Combo Pill Works in Trials - Bloomberg
Merck and Gilead discontinue lung cancer drug trial By Investing.com - Investing.com South Africa
Gilead and Merck’s once-weekly HIV pill meets trial goals - Investing.com
Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study - Lelezard
Merck and Gilead discontinue lung cancer drug trial - Investing.com
Gilead and Merck Announce Positive Topline Results From Two Phase 3 Studies Evaluating Islatravir/Lenacapavir, an Oral Once-Weekly HIV Treatment - Business Wire
Assembly Biosciences Teases Gilead HSV-2 Decision, Liver Disease Data Ahead - Yahoo Finance
Assessing Gilead Sciences (GILD) Valuation As Livdelzi Phase 3 PBC Results Shape Growth Expectations - simplywall.st
RBC Capital reiterates Gilead Sciences stock rating at Sector Perform By Investing.com - Investing.com South Africa
Gilead Sciences, Inc. $GILD Shares Bought by Erste Asset Management GmbH - MarketBeat
Clearbridge Investments LLC Reduces Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Holdings Raised by Brandywine Global Investment Management LLC - MarketBeat
Is Gilead Sciences (GILD) a Good Stock to Buy? - HarianBasis.co
Is Gilead Sciences, Inc. (GILD) A Good Stock To Buy Now? - Insider Monkey
Gilead Sciences, Inc. $GILD Shares Purchased by ING Groep NV - MarketBeat
Los Angeles Capital Management LLC Sells 676,504 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Capital World Investors Has $5.26 Billion Stake in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Shares Sold by Capital Research Global Investors - MarketBeat
Capital International Inc. CA Cuts Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
DB&C Advisors LLC Invests $1.57 Million in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences (GILD), Lakefront Biotherapeutics Acquire Ouro Medicines to Advance Autoimmune Pipeline - Yahoo Finance
Gilead Expands Into Autoimmune Orphan Diseases With Ouro Medicines Deal - simplywall.st
Westfield Capital Management Co. LP Takes $5.10 Million Position in Gilead Sciences, Inc. $GILD - MarketBeat
Vise Technologies Inc. Purchases 11,294 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
PBU The Pension Fund of Early Childhood & Youth Educators Purchases Shares of 95,333 Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Shares Sold by BI Asset Management Fondsmaeglerselskab A S - MarketBeat
길리어드 사이언스 (GILD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.39%
1.47%
자본화:
|
볼륨(24시간):